Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- Other: Serum proteomics
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 547
- Registration Number
- NCT01604798
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
Phase 2
Completed
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: FOLFOX6
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT01605305
A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Phase 3
Completed
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 436
- Registration Number
- NCT01591135
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 84
- Registration Number
- NCT01550848
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer
Terminated
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 9
- Registration Number
- NCT01543126
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 35
- Registration Number
- NCT01528826
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer
Phase 2
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT01526499
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
Phase 2
- Conditions
- Breast Cancer
- Interventions
- Drug: metroCX
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 72
- Registration Number
- NCT01526512
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia
Phase 2
Completed
- Conditions
- Pulmonary Disease
- Interventions
- Device: respiratory support
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 400
- Registration Number
- NCT01503801
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer
Phase 1
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2011-11-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT01474187
- Locations
- 🇨🇳
Cancer Hospital, Fudan University, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath